Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.

  • A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130)